What we do know is that less than 6% from the major MS research organizations around the globe—both governmental and not-for-profit organizations like mine—is spent on prevention. I think this is an unprecedented opportunity to prevent a debilitating neurological disease, which largely affects women, in the next generation, and probably in 10 years.
I think about where we've gone in the last 15 years; we have gone from three to 20 disease-modifying therapies that have produced the kinds of health outcomes that have reduced mortality by 30% and offset disability by 10-plus years. To be able to make those investments today is going to change the face of MS 10 years from now. There isn't another neurological disease, I don't think, in which you could make that claim with the evidence that's available to us today.
We're certainly asking the federal government to come in on that as a partner with a lot of concerned citizens who are going to give us money to partner on that. That's one of the specific requests that we've been making.